Company news
SKRR Exploration, Inc. news in 2007
SKRR Exploration, Inc.'s news releases, calls and decks from 2007, newest first.
Oncothyreon to begin trading today on NASDAQ and TSX
December 11, 2007
Court issues final order approving Biomira's move to U.S. and name change to Oncothyreon
December 5, 2007
Biomira Shareholders Approve Move to U.S.
December 4, 2007
Biomira Inc. receives Nasdaq delisting notification
November 5, 2007
Biomira Inc. announces date for special meeting of shareholders; Oncothyreon Inc. registration statement declared effective
November 1, 2007
Biomira announces third quarter 2007 financial results
November 1, 2007
Biomira to present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
October 30, 2007
New data may help guide the clinical development of Biomira's PX-478 and PX-866
October 24, 2007
Biomira to present at the BIO InvestorForum 2007
October 3, 2007
Biomira announces plan to change name to Oncothyreon
September 27, 2007
Biomira Announces Plan to Reincorporate in the United States
September 12, 2007
Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
September 5, 2007
Biomira initiates Phase 1 trial of PX-478 in patients with advanced metastatic cancers
August 28, 2007
Biomira and Merck KGaA sign amended and restated collaboration and supply agreements related to Stimuvax(R)
August 8, 2007
Biomira announces second quarter 2007 financial results
August 2, 2007
Biomira appoints industry veteran as Chief Operating Officer
July 17, 2007
Biomira files investigational new drug application for PX-478, a novel inhibitor of hypoxia-inducible factor-1 alpha
July 3, 2007
Biomira to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
May 8, 2007
Biomira Inc. announces first quarter 2007 results
April 26, 2007
Biomira selects PX-866 as clinical development candidate and presents promising preclinical data at AACR
April 16, 2007
Biomira reports Full year and Fourth Quarter 2006 Financial Results
March 8, 2007
Biomira to present at two upcoming investor conferences
March 7, 2007
Biomira restates U.S. GAAP note disclosure for non-cash charges
March 2, 2007
Biomira announces March 8th webcast of its fourth quarter and full year 2006 financial results conference call
March 2, 2007
First patient enrolled in Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer
February 26, 2007
Biomira to present at the BIO CEO & Investor Conference 2007
February 8, 2007
Eric Baker retires from Biomira's Board of Directors
January 22, 2007
Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer now open for patient enrollment
January 2, 2007
Phase II clinical trial of Biomira's PX-12 in patients with advanced pancreatic cancer now open for patient enrollment
January 2, 2007